Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Most relevant news about BASILEA PHARMACEUTICA AG
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli ..
GL
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26Basilea presents preclinical data on anti-angiogenic activity of derazantinib..
GL
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13Basilea reports interim results from phase 1/2 study FIDES-02 exploring deraz..
GL
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
AQ
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
AQ
10/12Basilea reports pooled efficacy data for derazantinib in iCCA patients with F..
GL
09/29BASILEA PHARMACEUTICA : initiates targeted biomarker-driven phase 2 study with l..
AQ
09/29BASILEA PHARMACEUTICA : initiates targeted biomarker-driven phase 2 study with l..
AQ
09/29Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin i..
GL
More most relevant news
All news about BASILEA PHARMACEUTICA AG
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli ..
GL
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26Basilea presents preclinical data on anti-angiogenic activity of derazantinib..
GL
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 ex..
AQ
10/13Basilea reports interim results from phase 1/2 study FIDES-02 exploring deraz..
GL
10/12BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA pa..
AQ
More news
News in other languages on BASILEA PHARMACEUTICA AG
10/28Basilea et Eli Lilly collaborent sur un traitement contre le cancer gastrique
10/28Basilea arbeitet bei Derazantinib-Studie mit Eli Lilly zusammen
10/26BASILEA : données positives sur Derazantinib contre certaines tumeurs
10/26Basilea präsentiert Daten zur anti-angiogenen Aktivität von Derazantinib
10/13Bourse Zurich: ouverture indécise, malgré la clôture en hausse de Wall Street
10/13Bourse Zurich: ouverture attendue en hausse dans le sillage de Wall Street
10/13BASILEA : résultat positif sur le derazantinib pour le cancer urothélial avancé
10/13Basilea legt Zwischenergebnisse zu Krebsmedikament Derazantinib vor
10/12Basilea présente des données positives sur le derazantinib
10/12Basilea legt an Fachkongress Daten zu Krebs-Kandidaten Derazantinib vor
Press releases
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreem..
AQ
10/28Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli ..
GL
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
10/26BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of..
AQ
More press releases
Upcoming event on BASILEA PHARMACEUTICA AG